Position of the Transparency Council – Opdivo (nivolumab)
At its meeting on 15 July 2024, the Transparency Council adopted position No. 67/2024 on the evaluation of the drug Opdivo (nivolumab) under the drug program “Treatment of patients with renal cell carcinoma (ICD-10: C64)” in combination with cabozantinib
Publication of the position >>